anti-SARS-CoV-2 convalescent plasma

BIOLOGICAL6 trials

Sponsors

University of Chicago, Orthosera Kft., Medical College of Wisconsin, U.S. Army Medical Research and Development Command, Institute for Transfusion Medicine of RNM

Conditions

COVID 19COVID-19Convalescent PlasmaCoronavirusCovid19SARS-CoV 2Severe Acute Respiratory Syndrome Coronavirus 2

Early Phase 1

COVID-19 Convalescent Plasma

CompletedNCT04340050

University of ChicagoCoronavirus

Start: 2020-04-10End: 2020-12-23Updated: 2024-02-28

Anti COVID-19 Convalescent Plasma Therapy

Orthosera Kft.COVID 19

Start: 2020-04-14End: 2021-09-01Target: 20Updated: 2021-02-25

Phase 2

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

CompletedNCT04354831

Medical College of WisconsinCOVID-19

Start: 2020-05-11End: 2021-02-10Updated: 2024-04-10

Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

TerminatedNCT04567173

University of the PhilippinesCovid19

Start: 2020-09-21End: 2021-06-30Updated: 2022-05-24

Unknown Phase

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

U.S. Army Medical Research and Development CommandSevere Acute Respiratory Syndrome Coronavirus 2

Updated: 2023-05-06

Efficacy and Safety of COVID-19 Convalescent Plasma

CompletedNCT04397523

Institute for Transfusion Medicine of RNMConvalescent Plasma, COVID-19, SARS-CoV 2

Start: 2020-04-30End: 2021-05-10Updated: 2024-05-28

Related Papers

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial

Life2022-10-092 citations